Porphyria cutanea tarda as a Predictor of Poor Response to Interferon Alfa Therapy in Chronic Hepatitis C

References

• Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976; 58: 1089–97.
   PubMed Web of Science ®Google Scholar
• Meissner PN, Hift RJ, Kirsch RE. The porphyrias. In: Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D, Shafritz DA, editors. The liver. Biology and pathobiology, 4th edn. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2001: 311–29.
   Google Scholar
• Elder GH. Porphyria cutanea tarda. Semin Liv Dis 1998;18: 67–75.
   PubMed Web of Science ®Google Scholar
• Bruguera M. Liver involvement in porphyria. Sem Dermatol 1986; 5: 178–85.
   Google Scholar
• Cortes JM, Oliva H, Paradinas FJ, Hernández Guio C. The pathology of the liver in porphyria cutanea tarda. Histopathology 1980; 4: 471–85.
   PubMed Web of Science ®Google Scholar
• Lefkowitch JH, Grossman ME. Hepatic pathology in porphyria cutanea tarda. Liver 1983;3: 19–29.
   PubMedGoogle Scholar
• Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27: 1661–9.
   PubMed Web of Science ®Google Scholar
• DeCastro M, Sánchez J, Herrera JF, Cháves A, Durán R, García-Buey L, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551–7.
   PubMed Web of Science ®Google Scholar
• Herrero C, Vicente A, Bruguera M, Ercilla MG, Barrera JM, Vidal J, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341: 778–89.
   Web of Science ®Google Scholar
• Moran MJ, Fontanellas A, Brudieux E, Hombrados I, De Ledinghen V, Couzigou P, et al. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection. Hepatology 1998; 27: 584–9.
   PubMed Web of Science ®Google Scholar
• Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–89.
   PubMed Web of Science ®Google Scholar
• Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferonalpha therapy in a case of chronic hepatitis C. Dig Dis Sci 1998; 43: 529–33.
   PubMed Web of Science ®Google Scholar
• Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997;44: 525–8.
   PubMed Web of Science ®Google Scholar
• Rich JD, Mylonakis E, Nossa R, Chapnick RM. Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. Dig Dis Sci 1999; 44: 1034–7.
   PubMed Web of Science ®Google Scholar
• Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13: 372–4.
   PubMed Web of Science ®Google Scholar
• Scheuer PJ, Lefkowitch JH. Disturbances of cooper and iron metabolism. In: Scheuer PJ, Lefkowitch JH, editors. Liver biopsy interpretation. Barcelona: W. B. Saunders; 2000: 270–83.
   Google Scholar
• Reichen J, Bianchi L, Buhler H, Dolivo N, Gonvers JJ, Lavanchy D, et al. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. Swiss Association for the Study of the Liver. J Hepatol 1996;25: 275–82.
   PubMed Web of Science ®Google Scholar
• Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26 Suppl 1: 122S–7S.
   Google Scholar
• Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1326–9.
   Google Scholar
• Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341: 1501–4.
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Marceliin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22: 1050–6.
   PubMed Web of Science ®Google Scholar
• Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634–9.
   PubMed Web of Science ®Google Scholar
• Grossman ME, Bickers DR, Poh-Fitzpatrick MB, Deleo VA, Harber LC. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1997;67: 277–86.
   Web of Science ®Google Scholar
• Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 321–3.
   PubMed Web of Science ®Google Scholar
• Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbatta N, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998; 27: 181–4.
   PubMed Web of Science ®Google Scholar
• Hift RJ, Kirsch RE. Porphyria cutanea tarda as a manifestation of alcohol-induced liver disease. In: Hall P, editor. Alcoholic liver disease, 2nd ed. London: Edward Arnold; 1995: 219–31.
   Google Scholar
• Deuffic S, Buffat L, Poynard T, Valieron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999;29: 1596–601.
   PubMed Web of Science ®Google Scholar
• Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon- related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepatol 2001;8: 1–18.
   PubMed Web of Science ®Google Scholar
• Bissell DM. Sex and hepatic fibrosis. Hepatology 1999;29: 988–99.
   PubMed Web of Science ®Google Scholar
• Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999;29: 719–27.
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997; 349: 825–32.
   PubMed Web of Science ®Google Scholar
• Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996; 20: 371A–7A.
   PubMed Web of Science ®Google Scholar
• Olynyk J, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104–9.
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994 20: 410–5.
   PubMed Web of Science ®Google Scholar
• Tannapfel A, Stölzel U, Köstler E, Melz S, Richter M, Keim V, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchow Arch 2001; 439: 1–5.
   PubMed Web of Science ®Google Scholar
• Jouet P, Roudot-Thoraval F, Dhumeaux D, Métreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients'with non-A, non-B, C hepatitis. Le Groupe Francais pour l'etude du traitement des hépatites chroniques NANB/C. Gastroenterology 1994; 106: 686–90.
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M., Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29: 214–23.
   Google Scholar
• Lamoril J, Andant C, Bogard C, Puy H, Gouya L, Pawlotsky JM, et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998; 27: 848–52.
   PubMed Web of Science ®Google Scholar